Clinical Trials Logo
  1. Home
  2. Myasthenia Gravis, Generalized
  3. NCT02565576

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Myasthenia Gravis, Generalized Clinical Trial

Official title:
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis

Clinical Trial Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of care in patients with moderate to severe myasthenia gravis (MG).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02565576
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date September 29, 2015
Completion date December 19, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT04115293 - Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis Phase 3
Recruiting NCT05737160 - Study of Telitacicept in Generalized Myasthenia Gravis Phase 3
Recruiting NCT04224506 - A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
Recruiting NCT06455709 - Markers of Favorable Response to Complement Inhibitors Therapy
Recruiting NCT04431895 - Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study Early Phase 1
Recruiting NCT05067348 - Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis Phase 2
Withdrawn NCT03165435 - A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis Phase 2/Phase 3
Recruiting NCT05214612 - Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Recruiting NCT05868837 - Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) Phase 3
Recruiting NCT06282159 - A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) Phase 2
Recruiting NCT04146051 - Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) Phase 2
Completed NCT03759366 - A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) Phase 3
Completed NCT02473952 - A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis Phase 2
Completed NCT00683969 - A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis Phase 3
Completed NCT03304054 - Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Phase 3
Recruiting NCT05716035 - Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis Phase 2/Phase 3